Medication reconciliation in ambulatory oncology.

Medication reconciliation in ambulatory oncology. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Medication reconciliation in ambulatory oncology. Abstract Text:

Saul N Weingart,Angela Cleary,Andrew Seger,Terry K Eng,Mark Saadeh,Anne Gross,Lawrence N Shulman,Saul N Weingart,Angela Cleary,Andrew Seger,Terry K Eng,Mark Saadeh,Anne Gross,Lawrence N Shulman,

BACKGROUND: Few models for medication reconciliation in ambulatory primary or specialty care have been described, perhaps because of the special challenges posed by this environment. METHODS: Dana-Farber Cancer Institute (Boston) created a reconciliation program that was designed as a patient-clinician partnership intervention. Policies that require clinicians to review and update medication lists at regular appointments were augmented. Clinic assistants printed patients' medication lists from the electronic medical record and distributed lists to established patients for review. Patients provided updated lists to their oncology clinicians. Clinicians then entered the information or indicated changes to be entered by a pharmacist. RESULTS: At baseline, 81% of patients' medication lists included at least one error or omission. With medication reconciliation, 90% of incorrect medication lists were updated. In contrast, only 2% of medication lists were corrected among patients who received "usual" care (p < .001). DISCUSSION: From the program's inception in November 2005 through August 2007, patients and staff reconciled 24,148 medication lists by making 53,040 changes to 168,475 listed drugs, a rate of 31 changes per 100 medications. Implementation required broad staff engagement and ongoing attention to operational issues.

Medication reconciliation in ambulatory oncology. Publishing Authors By Initials

SN Weingart,A Cleary,A Seger,TK Eng,M Saadeh,A Gross,LN Shulman,SN Weingart,A Cleary,A Seger,TK Eng,M Saadeh,A Gross,LN Shulman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Medication reconciliation in ambulatory oncology. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Joint Commission journal on quality and patient sa

VOLUME: 33

Page Numbers: 750-7

Journal Abbreviation:

ISSN: 1553-7250

DAY: 18

MONTH: Dec

YEAR: 2007

Medication reconciliation in ambulatory oncology. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101238023

Medication reconciliation in ambulatory oncology. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Medication reconciliation in ambulatory oncology. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Medication reconciliation in ambulatory oncology.

AFFILIATION: Center for Patient Safety, Dana-Farber Cancer Institute, Boston, USA. saul_weingart@dfci.harvard.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Jt Comm J Qual Patient Saf

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Medication reconciliation in ambulatory oncology Related Publications

• Acute ethanol toxicity from ingesting mouthwash in children younger than age 6, 1989-2003.
• Advanced environmental surveillance and molecular analyses indicate separate importations rather than endemic circulation of wild type 1 poliovirus in Gaza district in 2002.
• Androgens and menopause: more fuel for the fire.
• Be a sport (doc).
• Brachial neuralgia.
• Combination of flocculation tests in the differential diagnosis of jaundice.
• Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity.
• Dicumarol poisoning; report of a case.
• Impressions of physical medicine in the United States of America.
• Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men.
• Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.
• Isolation and properties of thyroglobulin-related 4S protein in the soluble fraction of thyroid tissue.
• Keeping the record straight.
• Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis.
• Medication reconciliation in ambulatory oncology.
• Microscopical observations on the effects of phenanthroline chelates on Landschütz ascites tumour cells.
• Mitochondrial GTP regulates glucose-stimulated insulin secretion.
• Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance.
• Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.
• New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy.
• Phenergan (R. P. 3277) preliminary report of clinical effectiveness.
• Psychopharmacology.
• Recurrent abdominal pain and irritable bowel syndrome in children.
• Rheumatic heart disease in developing countries.
• Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
• Texas dentists' attitudes toward the Dental Medicaid program.
• The blocking of antibodies in vivo; preliminary investigation.
• The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.
• We are advocates for kids.
• n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner.